Program Schedule

Multiple Sclerosis and Autoimmune Neurology Update 2019

Friday, February 8	3,	201	9
--------------------	----	-----	---

Noon	Registration
1:00 p.m.	Welcome and Announcements
1:05 p.m.	Biomarkers and MS Howard L. Weiner, M.D.
1:50 p.m.	Radiologically and Clinically Isolated Syndromes Orhun Kantarci, M.D.
2:10 p.m.	MS Diagnosis and Misdiagnosis Brian G. Weinshenker, M.D.
2:40 p.m.	Panel Discussion: Diagnosis Faculty
3:05 p.m.	Break
3:25 p.m.	MS and Comorbidities Visiting Faculty - TBD
4:05 p.m.	MS Neuroimaging Update Jan Mendelt Tillema, MD
4:35 p.m.	Case Vignettes and Panel Discussion Michel Toledano, M.D., Ralitza H. Gavrilova, M.D.
5:35 p.m.	Adjourn

Saturday, February 9, 2019

7:00 a.m.	Continental Breakfast
8:00 a.m.	Classical Autoimmune Disorders Andrew McKeon, M.D.
8:30 a.m.	Novel Autoimmune Synaptic Disorders Div Dubey, M.D.
9:00 am	Case Vignettes and Panel Discussion Anastasia Zekeridou and Fellows
9:30 a.m.	Break
9:45 a.m.	Neuromyelitis Optica Spectrum Disorders Nicholas Zalewski, M.D.
10:10 a.m.	Myelin Oligodendrocyte Glycoprotein Autoimmunity Sean J. Pittock, M.D.
10:35 a.m.	Imaging Pearls in Autoimmune Myelitis and its Mimics Eoin P. Flanagan, MD,
11:00 a.m.	Case Vignettes and Panel Discussion Dean Wingerchuk and Fellows
Noon	Lunch
Noon 1:00 p.m.	Lunch MS Pathology Claudia F. Lucchinetti, M.D.
	MS Pathology
1:00 p.m.	MS Pathology Claudia F. Lucchinetti, M.D. Progressive MS
1:00 p.m. 1:30 p.m.	MS Pathology Claudia F. Lucchinetti, M.D. Progressive MS W. Oliver Tobin, M.D. Panel Discussion
1:00 p.m. 1:30 p.m. 2:00 p.m.	MS Pathology Claudia F. Lucchinetti, M.D. Progressive MS W. Oliver Tobin, M.D. Panel Discussion Faculty
1:00 p.m. 1:30 p.m. 2:00 p.m. 2:15 p.m.	MS Pathology Claudia F. Lucchinetti, M.D. Progressive MS W. Oliver Tobin, M.D. Panel Discussion Faculty Break Current Therapeutic Strategies for MS
1:00 p.m. 1:30 p.m. 2:00 p.m. 2:15 p.m. 2:30 p.m	MS Pathology Claudia F. Lucchinetti, M.D. Progressive MS W. Oliver Tobin, M.D. Panel Discussion Faculty Break Current Therapeutic Strategies for MS B. Mark Keegan, M.D. Symptomatic Treatment in MS

Program is subject to change.